Davidson Michael H.
Insider CIK 1573785 · OMTH Executive VP & CMO · SLN Director · BIOA Director · NAMS Chief Executive Officer, Director · CLBS Director · TENX Director
Trades across companies
| Ticker | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|
| NAMS NewAmsterdam Pharma Co N.V | P Buy | 2026-09-14 | 2026-09-15 | 10,000 | $22.65 | $226.5K | 792,923 | SEC↗ |
| NAMS NewAmsterdam Pharma Co N.V | P Buy | 2026-09-14 | 2026-09-15 | 10,000 | $22.65 | $226.5K | 792,923 | SEC↗ |
| BIOA BioAge Labs, Inc. | A Award deriv | 2026-06-10 | 2026-06-12 | 22,000 | — | $0 | 22,000 | SEC↗ |
| NAMS NewAmsterdam Pharma Co N.V | M Exercise deriv | 2026-03-02 | 2026-03-02 | 443,707 | — | $0 | 239,267 | SEC↗ |
| NAMS NewAmsterdam Pharma Co N.V | M Exercise | 2026-03-02 | 2026-03-02 | 443,707 | — | $0 | 617,851 | SEC↗ |
| NAMS NewAmsterdam Pharma Co N.V | S Sale | 2026-03-02 | 2026-03-02 | 443,707 | $33.25 | $14.75M | 174,144 | SEC↗ |
| NAMS NewAmsterdam Pharma Co N.V | M Exercise deriv | 2026-02-26 | 2026-02-26 | 183,332 | — | $0 | 682,974 | SEC↗ |
| NAMS NewAmsterdam Pharma Co N.V | S Sale | 2026-02-26 | 2026-02-26 | 17,924 | $34.44 | $617.3K | 174,144 | SEC↗ |
| NAMS NewAmsterdam Pharma Co N.V | S Sale | 2026-02-26 | 2026-02-26 | 165,408 | $33.63 | $5.56M | 477,783 | SEC↗ |
| NAMS NewAmsterdam Pharma Co N.V | M Exercise | 2026-02-26 | 2026-02-26 | 183,332 | — | $0 | 643,191 | SEC↗ |
| NAMS NewAmsterdam Pharma Co N.V | M Exercise deriv | 2026-02-25 | 2026-02-26 | 58,253 | — | $0 | 866,306 | SEC↗ |
| NAMS NewAmsterdam Pharma Co N.V | S Sale | 2026-02-25 | 2026-02-26 | 1,300 | $36.68 | $47.7K | 459,859 | SEC↗ |
| NAMS NewAmsterdam Pharma Co N.V | S Sale | 2026-02-25 | 2026-02-26 | 10,436 | $35.96 | $375.3K | 461,159 | SEC↗ |
| NAMS NewAmsterdam Pharma Co N.V | S Sale | 2026-02-25 | 2026-02-26 | 46,517 | $35.11 | $1.63M | 471,595 | SEC↗ |
| NAMS NewAmsterdam Pharma Co N.V | M Exercise | 2026-02-25 | 2026-02-26 | 58,253 | — | $0 | 518,112 | SEC↗ |
| NAMS NewAmsterdam Pharma Co N.V | M Exercise deriv | 2026-02-24 | 2026-02-26 | 64,708 | — | $0 | 924,559 | SEC↗ |
| NAMS NewAmsterdam Pharma Co N.V | S Sale | 2026-02-24 | 2026-02-26 | 3,161 | $36.46 | $115.3K | 459,859 | SEC↗ |
| NAMS NewAmsterdam Pharma Co N.V | S Sale | 2026-02-24 | 2026-02-26 | 61,547 | $36.13 | $2.22M | 463,020 | SEC↗ |
| NAMS NewAmsterdam Pharma Co N.V | M Exercise | 2026-02-24 | 2026-02-26 | 64,708 | — | $0 | 524,567 | SEC↗ |
| TENX TENAX THERAPEUTICS, INC. | A Award deriv | 2026-01-09 | 2026-01-13 | 30,000 | — | $0 | 30,000 | SEC↗ |
| NAMS NewAmsterdam Pharma Co N.V | A Award deriv | 2026-01-07 | 2026-01-09 | 364,000 | — | $0 | 364,000 | SEC↗ |
| NAMS NewAmsterdam Pharma Co N.V | S Sale | 2026-01-07 | 2026-01-09 | 11,582 | — | $0 | 378,859 | SEC↗ |
| NAMS NewAmsterdam Pharma Co N.V | A Award | 2026-01-07 | 2026-01-09 | 81,000 | — | $0 | 459,859 | SEC↗ |
| TENX TENAX THERAPEUTICS, INC. | A Award deriv | 2025-07-01 | 2025-07-03 | 80,000 | — | $0 | 80,000 | SEC↗ |
| BIOA BioAge Labs, Inc. | A Award deriv | 2025-06-05 | 2025-06-09 | 22,000 | — | $0 | 22,000 | SEC↗ |
| NAMS NewAmsterdam Pharma Co N.V | A Award deriv | 2025-03-26 | 2025-03-28 | 38,394 | — | $0 | 38,394 | SEC↗ |
| NAMS NewAmsterdam Pharma Co N.V | M Exercise deriv | 2025-03-26 | 2025-03-28 | 38,394 | — | $0 | 0 | SEC↗ |
| NAMS NewAmsterdam Pharma Co N.V | A Award | 2025-03-26 | 2025-03-28 | 30,992 | — | $0 | 364,305 | SEC↗ |
| NAMS NewAmsterdam Pharma Co N.V | S Sale | 2025-03-26 | 2025-03-28 | 12,258 | — | $0 | 390,441 | SEC↗ |
| NAMS NewAmsterdam Pharma Co N.V | M Exercise | 2025-03-26 | 2025-03-28 | 38,394 | — | $0 | 402,699 | SEC↗ |
| NAMS NewAmsterdam Pharma Co N.V | A Award | 2025-01-07 | 2025-01-07 | 123,529 | — | $0 | 123,529 | SEC↗ |
| NAMS NewAmsterdam Pharma Co N.V | A Award deriv | 2025-01-06 | 2025-01-07 | 670,467 | — | $0 | 670,467 | SEC↗ |
| SLN Silence Therapeutics plc | A Award deriv | 2025-01-02 | 2025-01-06 | 48,000 | — | $0 | 48,000 | SEC↗ |
| TENX TENAX THERAPEUTICS, INC. | A Award deriv | 2024-12-10 | 2024-12-12 | 100,000 | — | $0 | 100,000 | SEC↗ |
| NAMS NewAmsterdam Pharma Co N.V | G Gift deriv | 2024-10-09 | 2024-10-11 | 15,000 | $11.50 | $172.5K | 85,000 | SEC↗ |
| BIOA BioAge Labs, Inc. | A Award deriv | 2024-09-25 | 2024-09-27 | 15,000 | — | $0 | 15,000 | SEC↗ |
| NAMS NewAmsterdam Pharma Co N.V | P Buy | 2024-08-20 | 2024-08-22 | 5,000 | $16.27 | $81.3K | 209,784 | SEC↗ |
| TENX TENAX THERAPEUTICS, INC. | P Buy deriv | 2024-08-08 | 2024-08-08 | 25,000 | — | $0 | 25,000 | SEC↗ |
| TENX TENAX THERAPEUTICS, INC. | P Buy deriv | 2024-08-08 | 2024-08-08 | 47,500 | — | $0 | 47,500 | SEC↗ |
| TENX TENAX THERAPEUTICS, INC. | P Buy | 2024-08-08 | 2024-08-08 | 2,500 | — | $0 | 2,881 | SEC↗ |
| NAMS NewAmsterdam Pharma Co N.V | P Buy | 2024-06-20 | 2024-06-24 | 5,000 | $17.26 | $86.3K | 204,784 | SEC↗ |
| BIOA BioAge Labs, Inc. | A Award deriv | 2024-03-26 | 2024-09-27 | 33,986 | — | $0 | 33,986 | SEC↗ |
| NAMS NewAmsterdam Pharma Co N.V | A Award deriv | 2024-01-01 | 2024-01-03 | 1,039,939 | — | $0 | 1,039,939 | SEC↗ |
| TENX TENAX THERAPEUTICS, INC. | A Award deriv | 2022-06-09 | 2022-06-10 | 5,000 | — | $0 | 5,000 | SEC↗ |
| CLBS CALADRIUS BIOSCIENCES, INC | A Award | 2022-01-10 | 2022-01-12 | 65,430 | — | $0 | 209,753 | SEC↗ |
| TENX TENAX THERAPEUTICS, INC. | M Exercise deriv | 2021-06-11 | 2021-06-15 | 512 | — | $0 | 0 | SEC↗ |
| TENX TENAX THERAPEUTICS, INC. | A Award | 2021-06-11 | 2021-06-15 | 512,000 | — | $0 | 606,645 | SEC↗ |
| TENX TENAX THERAPEUTICS, INC. | A Award deriv | 2021-06-10 | 2021-06-15 | 6,250 | — | $0 | 6,250 | SEC↗ |
| CLBS CALADRIUS BIOSCIENCES, INC | A Award | 2021-01-11 | 2021-01-12 | 37,735 | — | $0 | 144,323 | SEC↗ |
| CLBS CALADRIUS BIOSCIENCES, INC | P Buy | 2020-09-09 | 2020-09-10 | 55,525 | $1.80 | $99.9K | 106,588 | SEC↗ |
| CLBS CALADRIUS BIOSCIENCES, INC | A Award | 2020-07-28 | 2020-08-12 | 51,063 | $2.35 | $120.0K | 51,063 | SEC↗ |
| OMTH Omthera Pharmaceuticals, I | D To issuer | 2013-07-18 | 2013-07-18 | 520,756 | — | $0 | 0 | SEC↗ |
| OMTH Omthera Pharmaceuticals, I | D To issuer | 2013-07-18 | 2013-07-18 | 964,587 | — | $0 | 0 | SEC↗ |
| OMTH Omthera Pharmaceuticals, I | C Conversion deriv | 2013-04-16 | 2013-04-17 | 72,500 | — | $0 | 0 | SEC↗ |
| OMTH Omthera Pharmaceuticals, I | C Conversion | 2013-04-16 | 2013-04-17 | 51,960 | — | $0 | 964,587 | SEC↗ |